Showing results (11-20 of 140) with videos related to
Sort By:
Pageof 14
Current Drug Targets|June 13, 2009
Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABLMassimo Breccia, Giuliana AlimenaExpert Review of Hematology|November 29, 2014
Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approachMassimo Breccia, Giuliana AlimenaExpert Opinion on Therapeutic Targets|September 23, 2010
NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemiaMassimo Breccia, Giuliana AlimenaCancer Letters|March 28, 2012
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantagesMassimo Breccia, Giuliana AlimenaAnnals of Hematology|February 19, 2013
Efficacy and safety of deferasirox in myelodysplastic syndromesMassimo Breccia, Giuliana AlimenaLeukemia Research|March 12, 2013
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitorsMassimo Breccia, Giuliana AlimenaExpert Opinion on Drug Safety|August 21, 2010
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their developmentMassimo Breccia, Giuliana AlimenaExpert Opinion on Pharmacotherapy|July 5, 2011
The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard doseMassimo Breccia, Giuliana AlimenaCritical Reviews in Oncology/Hematology|January 28, 2012
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety dataMassimo Breccia, Mario Tiribelli, Giuliana AlimenaLeukemia Research|December 3, 2014
How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated reviewMassimo Breccia, Matteo Molica, Giuliana AlimenaPageof 14